Quick Facts

• Main Therapeutic Uses: Treatment of active Crohn’s disease affecting the ileum and/or ascending colon; induction of remission in active microscopic colitis (collagenous and lymphocytic colitis).

---

Intesticort contains budesonide, which is used for the management of chronic inflammatory diseases of the intestine. The medication is primarily prescribed to treat mild to moderate active Crohn’s disease when the inflammation is localized to the lower part of the small bowel (ileum) and/or the beginning of the large bowel (ascending colon). The intended benefit in this use is to induce a state of remission.

Another significant use is for the treatment of microscopic colitis, including its subtypes, collagenous colitis and lymphocytic colitis, which involve chronic inflammation of the large intestine. The goal of this treatment is also to induce a period of remission. The formulation is designed to release the active substance in a targeted manner to the affected areas of the intestinal tract.

Intesticort, a formulation of the corticosteroid budesonide, is generally reserved for specific patient populations, with several mandatory exclusions and restrictions defined by regulatory bodies.

Contraindications and Groups to Avoid

• Hypersensitivity: The medicine is contraindicated for any individual with a known allergy or hypersensitivity to budesonide or any of the product's inactive ingredients.
• Severe Hepatic Impairment: Use is not recommended in patients with severe liver disease (Child-Pugh Class C) due to the substantial increase in the drug’s systemic exposure and the risk of hypercorticism and adrenal axis suppression.

Restricted or Cautionary Use

Population / Condition	Eligibility Status
Pediatric Use	Established for patients 8 years of age and older. Safety and efficacy are not established for children under 8.
Moderate Hepatic Impairment	Use with caution; patients should be monitored for signs of increased systemic steroid effect (hypercorticism).
Infections	Use with caution (if at all) in patients with active or quiescent tuberculosis, untreated systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex.
Pre-existing Conditions	Caution is advised for patients with hypertension, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma, or cataracts (or a family history of diabetes/glaucoma), as the systemic corticosteroid effects may worsen these conditions.
Pregnancy	Use only if the potential benefit justifies the potential risk, as animal studies indicate the possibility of fetal harm.

These official rules strictly define who is eligible, focusing on hypersensitivity, liver function, age, and managing the risk of infection or exacerbation of steroid-sensitive diseases.

Interactions with other medicines and products

The interaction profile of Intesticort (budesonide) is primarily driven by its metabolism through the Cytochrome P450 3A4 (CYP3A4) enzyme. Interference with this enzyme is the official basis for documented interaction patterns that can significantly alter the drug's systemic exposure.

Formally Documented Restrictions

Interaction Type	Examples / Description	Official Outcome / Constraint
Contraindicated Combinations	Lopinavir, Mifepristone, and Ribociclib are formally prohibited in regulatory labels.	Combination is contraindicated due to risk of increased budesonide systemic exposure.
Potent CYP3A4 Inhibitors	Ketoconazole, Ritonavir, and Erythromycin are documented inhibitors.	Co-administration causes a multi-fold increase in systemic exposure and reduced clearance of budesonide.
Potent CYP3A4 Inducers	Carbamazepine officially listed.	Co-administration leads to a documented decrease in systemic exposure by accelerating metabolism.
Food Restriction	Grapefruit and Grapefruit Juice are restricted.	Consumption is officially advised to be avoided as it increases systemic exposure via CYP3A4 inhibition in the gut wall.
Population-Specific Note	Patients with severe hepatic impairment (Child-Pugh Class C).	Reduced elimination results in officially documented increased systemic availability, requiring avoidance in this population.

If co-administration with a potent CYP3A4 inhibitor is unavoidable, regulatory labeling advises that a separation of dosing times should be considered to mitigate the increase in systemic exposure. The entire profile is based on pharmacokinetic alterations and resulting constraints.

How Intesticort Works: Mechanism of Action

Intesticort's action is governed by two core, interlinked mechanisms that localize its effect to the gut lining while minimizing systemic activity.

---

Targeted Anti-Inflammatory Gene Modulation

Intesticort acts as a high-affinity agonist (activator) of the Glucocorticoid Receptor (GR), a protein inside cells of the immune system and the gut lining. This activation triggers the downregulation of genes responsible for producing pro-inflammatory substances (like cytokines), while simultaneously upregulating proteins that regulate inflammation. This molecular mechanism results in the suppression of excessive mediator activity, leading to a reduction in local tissue inflammation.

---

Mechanism of Restricted Systemic Distribution

This domain addresses the drug's unique pharmacokinetic behavior. After absorption from the intestine, the majority of the drug undergoes rapid inactivation by the CYP3A4 enzyme in the liver (the first-pass effect). This process ensures that high concentrations of the active drug remain locally in the gut wall to modulate inflammatory pathways, while only a small fraction enters the systemic circulation, which limits glucocorticoid effects on distant tissues.

How to Use Intesticort (Budesonide) Delayed-Release Capsules

Intesticort (budesonide) delayed-release capsules are administered orally, and the instructions for use must be followed precisely to ensure the drug reaches its intended site of action in the lower intestine.

Official Administration Guidelines

Guideline	Instruction
Route of Administration	Oral
Frequency and Timing	Take once daily in the morning.
Preparation	Swallow the capsule whole. Do not chew, crush, or break the capsule, as this affects its controlled release.
Alternative Preparation	If unable to swallow whole, open the capsule and empty the granules onto one tablespoon of applesauce. Consume the entire mixture immediately (within 30 minutes) and follow with eight ounces of cool water. Do not chew the granules.
Dosing (Adults)	Active Disease: 9 mg once daily for up to 8 weeks. Maintenance: 6 mg once daily for up to 3 months.
Age-Specific Use	Indicated for patients 8 years of age and older who weigh more than 25 kg.
Special Condition	Avoid consumption of grapefruit or grapefruit juice throughout therapy.
Missed Dose	If a dose is missed, take it as soon as possible. If it is almost time for the next dose, skip the missed dose. Do not take double or extra doses.

Discontinuation and Tapering

This medication should not be stopped abruptly. The dose must be gradually reduced (tapered) over the last two to four weeks of therapy as directed by the prescribing physician. This controlled reduction process is mandatory to allow the body's natural systems to adjust.

Evidence for Use in Mild-to-Moderate Crohn’s Disease

Research examined Intesticort in individuals with Crohn’s disease who were experiencing periods of heightened symptom activity. The research was primarily conducted through short-term Randomized Controlled Trials (RCTs) and systematic reviews, focusing on inflammation observed in the terminal ileum and/or the ascending colon. The research explored whether patients achieved predefined measurements of Clinical Remission. Findings describe patterns observed in the studies where a larger group of patients reached measured remission thresholds compared to the placebo group. Trials described different patterns of measured outcomes when compared to conventional systemic steroids. The evidence base for short-term symptom changes is broadly classified as having Moderate certainty.

---

Evidence for Use in Microscopic Colitis

Intesticort was studied for use in microscopic colitis in multiple short-term RCTs and long-term observational studies, exploring the medicine's application for both the collagenous colitis and lymphocytic colitis subtypes. The studies focused on achieving both Clinical Remission and Histological Remission. Findings describe patterns observed where a larger number of patients achieved these measured outcomes compared to placebo in the short term. The evidence for induction of remission in both subtypes is classified as High certainty. Follow-up research highlights observations of frequent recurrence of symptoms after study treatment was concluded.

---

Long-Term Studies and Durability of Response

Research has explored outcomes beyond the initial treatment phase, particularly regarding the durability of the initial measured response. Follow-up durations were limited for Crohn's disease, and available data indicate varying and often mixed findings regarding the patterns observed with continued use to maintain low disease activity. Long-term measured outcomes are not fully established for either condition, and studies examining prolonged continuous use are still emerging.

---

Evidence in Specific Patient Groups and Disease Extent

Clinical research has included specific populations, such as pediatric patients and the typically older adult demographic presenting with microscopic colitis. However, the certainty of the evidence varies across studies, and sample sizes were modest for some of these subgroups. The research describes limitations regarding its findings for patients whose Crohn’s disease inflammation is located outside of the ileum and ascending colon.

---

Research Gaps and What Remains Uncertain

Several key areas highlight where research is ongoing or where data are still emerging. Specifically, the high rate of relapse in microscopic colitis after treatment cessation suggests a critical research gap in understanding long-term maintenance strategies. For Crohn's disease, comparative evidence is lacking for patients with more severe symptoms, as the focus has been predominantly on mild-to-moderate disease activity. The evidence highlights what is known—and what is still uncertain—about the medicine’s role in these conditions.

Common questions about Intesticort (FAQ)

---

Q: How long does it usually take to notice an effect from Intesticort?

A: According to official product information, the active ingredient is absorbed and typically reaches its highest level in the blood within 2 to 8 hours after administration. This pharmacokinetic data relates to when the medication is in the system. However, the regulatory documents do not specify a clinical timeframe for when symptom improvement may be noticeable.

Q: Can Intesticort cause weight gain?

A: The official product information does not consistently list general weight gain as a common side effect for this specific formulation. However, because Intesticort is a corticosteroid, official documents report the possibility of signs related to hypercorticism. These signs can include changes in fat distribution associated with the corticosteroid class.

Q: I'm taking Intesticort—is it normal to feel more tired?

A: Official documents state that fatigue (tiredness) is listed as a common adverse reaction for Intesticort. In clinical trials, this side effect, along with pain, was reported in 5% or more of adult patients.

Q: Does Intesticort affect sleep?

A: According to official post-marketing reports, adverse events related to sleep have been documented with the use of this medicine. These documented experiences include trouble sleeping (insomnia) and general changes in sleep patterns.

Q: Can Intesticort impact my mood or cause anxiety?

A: Official regulatory information indicates that this medication can affect mood. Post-marketing reports have included experiences such as mood changes, mood swings, anxiety, nervousness, and depression.

Q: Does Intesticort interact with birth control pills?

A: Intesticort (budesonide) is processed in the body by the CYP3A4 enzyme. Because certain oral contraceptive agents are known to inhibit this enzyme, the potential for a clinically relevant interaction exists. This interaction could increase the amount of budesonide circulating throughout the body.

Q: Can people who are lactose intolerant take Intesticort?

A: The official product information states that the capsule formulation contains lactose monohydrate as an inactive ingredient. The medicine is contraindicated for people with rare hereditary problems related to certain sugar malabsorptions. Caution is advised for patients known to be sensitive to these ingredients.

Q: How often do I need to see my doctor while on Intesticort?

A: While the official drug labels do not specify a set frequency for general follow-up visits, they mandate specific monitoring. This includes checking for signs of hypercorticism and adrenal axis suppression. Pediatric patients also require regular growth monitoring throughout treatment.

Q: Are there any required blood tests when taking Intesticort?

A: Regulatory documents advise that certain diagnostic tests, such as the ACTH stimulation test for pituitary insufficiency, might yield inaccurate results while taking this medication. Patients switching from systemic steroids or those with moderate liver impairment may require monitoring of their adrenocortical function.

Q: Does research show Intesticort is used for any conditions other than Crohn's disease or Colitis?

A: Yes, the active ingredient in Intesticort, budesonide, is used in other approved formulations. These formulations are officially used for conditions such as Autoimmune Hepatitis and Ulcerative Colitis.

Q: Are there different brand names for the medicine in Intesticort?

A: The active ingredient in Intesticort is budesonide. The budesonide delayed-release capsule is available under various brand names in different regions. Examples include Entocort and Ortikos in the US, and Budenofalk in Europe.

Q: Is the strength of the side effects dose-dependent?

A: Official product information notes that systemic effects, such as adrenal axis suppression, are often associated with dose and duration of corticosteroid exposure. Clinical trial data also shows a slight numerical difference in the frequency of some adverse reactions between the higher and lower dosages of the medication.

Q: What if I need surgery—do I need to stop Intesticort?

A: Corticosteroids can lessen the body’s natural ability to cope with physical stress. Official regulatory warnings discuss the potential need for supplementation with a systemic corticosteroid for patients facing trauma, surgery, or other stressful situations.

Q: What should I do if I experience blurred vision while taking Intesticort?

A: Official product warnings indicate that visual disturbances, including blurred vision, have been reported with the use of glucocorticoids. Regulatory guidance notes that visual disturbances may require evaluation by an eye specialist (ophthalmologist) to check for possible eye conditions such as cataracts or glaucoma.

Q: Does Intesticort interact with common pain relievers like ibuprofen?

A: According to documented interaction information, using Intesticort (budesonide) alongside nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may increase the possibility of increased risk for certain gastrointestinal side effects. These include inflammation, bleeding, and ulceration in the digestive tract.

Q: Is Intesticort a commonly prescribed first-line treatment?

A: Official guidelines and clinical reviews sometimes position this medication as an alternative first-line or preferred option for specific patient groups and conditions. Its profile, which includes localized action, contributes to its use in these specific settings.

Q: Will Intesticort show up on a standard drug test?

A: Official regulatory guidance includes a note to inform healthcare providers and laboratory personnel that the active ingredient budesonide is being taken prior to any laboratory test.

Q: Is it better to take the dose with or without food?

A: Official administration guidelines state that the extended-release capsule should be taken once daily in the morning. The regulatory information does not specify a general requirement to take the capsule with or without a full meal, but it strictly advises that grapefruit or grapefruit juice must be avoided during therapy.

Q: Can Intesticort cause dizziness or lightheadedness?

A: Official product information lists dizziness as a common adverse reaction associated with this medication. In clinical trials, this side effect occurred in 5% or more of adult patients.

This information details the official regulatory requirements for the storage, handling, and disposal of Intesticort, based on authoritative government-issued drug labels (e.g., Summary of Product Characteristics).

Official Storage Requirements

Storage Factor	Requirement
Temperature	Do not store above 30 C.
Protection	Store in the original container to protect from light and moisture.
Handling	Replace cap firmly after use.
Child Safety	Keep this medicine out of the sight and reach of children.
Shelf-Life	The documented shelf life is 3 years (in the original, unopened container).

Disposal

• Unused Product: Any unused medicinal product or waste material must be disposed of in accordance with local requirements.

---

Regulatory documents mandate specific temperature controls and environmental protection to ensure product stability throughout its shelf life. The official profile requires strict adherence to container-related rules to prevent degradation from light or moisture. Final elimination of the product must follow established local regulatory procedures for pharmaceutical waste.